within Pharmacolibrary.Drugs.ATC.V;

model V04CG05
  extends Pharmacokinetic.Models.PK_2C(
    weight         = 70,
    F              = 1,
    Cl             = 5.833333333333333e-05,
    adminDuration  = 600,
    adminMass      = 2 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.003,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,            
    Vdp             = 0.0075,
    k12             = 5.5,
    k21             = 5.5
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>V04CG05</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Methylthioninium chloride, commonly known as methylene blue, is a synthetic dye that has been used as a medication for the treatment of methemoglobinemia and as a diagnostic agent. It has also seen use in the management of ifosfamide-induced encephalopathy and, previously, in urinary tract infections. Methylene blue is currently approved for use in treating methemoglobinemia but is also under investigation for potential nootropic and neuroprotective effects in Alzheimer's disease.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in healthy adult volunteers following a single intravenous administration.</p><h4>References</h4><ol><li><p>Clifton, J, &amp; Leikin, JB (2003). Methylene blue. <i>American journal of therapeutics</i> 10(4) 289–291. DOI:<a href=&quot;https://doi.org/10.1097/00045391-200307000-00009&quot;>10.1097/00045391-200307000-00009</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/12845393/&quot;>https://pubmed.ncbi.nlm.nih.gov/12845393</a></p></li><li><p>Workum, JD, et al., &amp; van den Berg, MJW (2019). [Autointoxication with &#x27;suicide powder&#x27;]. <i>Nederlands tijdschrift voor geneeskunde</i> 163 –. PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/30875162/&quot;>https://pubmed.ncbi.nlm.nih.gov/30875162</a></p></li><li><p>Kunos, CA, et al., &amp; Hoppel, CL (2012). Management of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone-induced methemoglobinemia. <i>Future oncology (London, England)</i> 8(2) 145–150. DOI:<a href=&quot;https://doi.org/10.2217/fon.11.147&quot;>10.2217/fon.11.147</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/22335579/&quot;>https://pubmed.ncbi.nlm.nih.gov/22335579</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end V04CG05;
